BullFrog AI Holdings is a digital biopharmaceutical company. Co. is focused on developing AI/ML-driven analysis of complex data sets in medicine and healthcare. Co. is deploying bfLEAP for use at several stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development. Co.'s other products include siRNA which targets Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Mebendazole for the treatment of Glioblastoma. The BFRG average annual return since 2023 is shown above.
The Average Annual Return on the BFRG average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BFRG average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BFRG average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|